For the twelve months ended Jul 4, 2026, USANA Health Sciences Inc. reported $913.36M of revenue and -$22.16M of net income.
USNA revenue was $223.27M in fiscal Q2 2026 (ended Jul 4, 2026), down 5.3% from a year earlier and down 10.8% from the prior quarter. For the full fiscal 2025 it was $925.26M, up 8.3% from fiscal 2024. Compound annual growth was -4.0% over 5 years. It rose in 5 of the last 9 fiscal years.
USNA net income was -$21.38M in fiscal Q2 2026 (ended Jul 4, 2026), compared with $9.65M a year earlier. For the full fiscal 2025 it was $10.76M, down 74.4% from fiscal 2024. Compound annual growth was -38.7% over 5 years and -19.5% over 10 years. It rose in 3 of the last 10 fiscal years.
USNA diluted EPS was -$1.16 in fiscal Q2 2026 (ended Jul 4, 2026), compared with $0.52 a year earlier. For the full fiscal 2025 it was $0.58, down 73.5% from fiscal 2024. Compound annual growth was -37.0% over 5 years and -16.7% over 10 years.
USNA free cash flow was $20.16M in fiscal Q2 2026 (ended Jul 4, 2026), up 180.4% from a year earlier and up 183.4% from the prior quarter. For the full fiscal 2025 it was $8.53M, down 83.3% from fiscal 2024. Compound annual growth was -43.3% over 5 years and -20.8% over 10 years. It rose in 4 of the last 10 fiscal years.
| Line item | Jan 3, 2026 | Dec 28, 2024 | Dec 30, 2023 | Dec 31, 2022 | Jan 1, 2022 | Jan 2, 2021 | Dec 28, 2019 | Dec 29, 2018 | Dec 30, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $925.26M | $854.50M | $921.01M | $998.60M | $1.19B | $1.13B | $1.06B | $1.19B | $1.05B | $1.01B |
| Cost of revenue | $200.85M | $161.21M | $176.69M | $193.89M | $217.90M | $209.11M | $187.50M | $200.71M | $179.40M | $180.19M |
| Gross profit | $724.40M | $693.29M | $744.32M | $804.71M | $968.57M | $925.53M | $873.40M | $988.54M | $867.86M | $825.89M |
| Research and development | $10.69M | $11.57M | $11.45M | $11.56M | $11.11M | $10.63M | $10.26M | $10.24M | $8.95M | $8.84M |
| Selling, general and admin | $337.37M | $263.27M | $256.99M | $262.30M | $279.11M | $261.19M | $267.73M | $275.06M | $265.09M | $234.19M |
| Operating income | $37.43M | $66.32M | $93.07M | $107.61M | $170.19M | $176.49M | $146.19M | $188.35M | $132.50M | $138.62M |
| Interest expense | $842.0K | $281.0K | $262.0K | $192.0K | $57.0K | $507.0K | $66.0K | $36.0K | $46.0K | $444.0K |
| Pre-tax income | $41.53M | $76.35M | $102.45M | $108.62M | $170.64M | $177.95M | $150.50M | $191.51M | $134.64M | $138.55M |
| Income tax | $30.05M | $34.29M | $38.66M | $39.27M | $54.14M | $53.28M | $49.97M | $65.29M | $72.11M | $38.51M |
| Net income | $10.76M | $42.03M | $63.79M | $69.35M | $116.50M | $124.66M | $100.53M | $126.22M | $62.53M | $100.04M |
| EPS, basic | $0.58 | $2.20 | $3.31 | $3.60 | $5.78 | $5.89 | $4.44 | $5.24 | $2.57 | $4.14 |
| EPS, diluted | $0.58 | $2.19 | $3.30 | $3.59 | $5.73 | $5.86 | $4.41 | $5.12 | $2.53 | $3.99 |
| Diluted shares | 18.6M | 19.2M | 19.3M | 19.3M | 20.3M | 21.3M | 22.8M | 24.6M | 24.7M | 25.0M |
| Line item | Jan 3, 2026 | Dec 28, 2024 | Dec 30, 2023 | Dec 31, 2022 | Jan 1, 2022 | Jan 2, 2021 | Dec 28, 2019 | Dec 29, 2018 | Dec 30, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $158.38M | $181.77M | $330.42M | $288.42M | $239.83M | $311.92M | $234.83M | $214.33M | $247.13M | $178.95M |
| Receivables | $4.29M | - | - | - | - | - | - | - | - | - |
| Inventory | $102.61M | $69.73M | $61.45M | $67.09M | $98.32M | $90.22M | $68.91M | $81.95M | $62.92M | $64.81M |
| Current assets | $288.40M | $279.19M | $417.75M | $384.38M | $365.12M | $425.29M | $329.28M | $392.33M | $340.16M | $277.86M |
| Goodwill | $137.96M | $144.17M | $17.10M | $17.37M | $17.67M | $17.37M | $16.64M | $16.82M | $17.42M | $16.71M |
| Total assets | $742.91M | $748.19M | $632.76M | $596.55M | $577.74M | $640.89M | $516.93M | $554.46M | $519.27M | $470.64M |
| Current liabilities | $128.56M | $139.63M | $118.84M | $143.83M | $160.79M | $168.07M | $136.10M | $148.69M | $141.18M | $138.49M |
| Total liabilities | $156.64M | $161.86M | $135.56M | - | - | - | - | - | - | - |
| Shareholders' equity | $533.10M | $532.11M | $497.20M | $434.47M | $395.12M | $441.65M | $351.71M | $391.15M | $363.21M | $325.29M |
| Line item | Jan 3, 2026 | Dec 28, 2024 | Dec 30, 2023 | Dec 31, 2022 | Jan 1, 2022 | Jan 2, 2021 | Dec 28, 2019 | Dec 29, 2018 | Dec 30, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $22.35M | $60.99M | $70.64M | $103.90M | $121.23M | $160.40M | $126.73M | $152.12M | $123.77M | $136.89M |
| Capital expenditures | $13.82M | $10.07M | $14.49M | $10.40M | $12.76M | $15.09M | $16.57M | $11.43M | $13.22M | $32.70M |
| Free cash flow | $8.53M | $50.92M | $56.15M | $93.50M | $108.46M | $145.31M | $110.16M | $140.69M | $110.55M | $104.19M |
| Investing cash flow | -$10.13M | -$213.09M | -$11.97M | -$12.37M | -$14.19M | -$33.96M | $47.49M | -$69.00M | -$12.90M | -$31.88M |
| Financing cash flow | -$40.60M | $9.55M | -$14.24M | -$30.09M | -$181.41M | -$59.44M | -$152.05M | -$105.28M | -$50.32M | -$64.86M |
| Share repurchases | $27.51M | $9.44M | $11.60M | $25.38M | $177.84M | $57.03M | $150.00M | $105.38M | $50.00M | $64.61M |
| Stock-based compensation | $13.83M | $14.56M | $14.60M | $13.33M | $14.30M | $14.39M | $15.54M | $14.96M | $15.48M | $16.54M |
| Depreciation and amortization | $32.56M | $14.54M | $12.70M | $13.39M | $13.04M | $13.75M | $14.74M | $16.84M | $16.11M | $13.48M |
| Line item | Jan 3, 2026 | Dec 28, 2024 | Dec 30, 2023 | Dec 31, 2022 | Jan 1, 2022 | Jan 2, 2021 | Dec 28, 2019 | Dec 29, 2018 | Dec 30, 2017 | Dec 31, 2016 |
|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | 8.3% | -7.2% | -7.8% | -15.8% | 4.6% | 7.0% | -10.8% | 13.6% | 4.1% | - |
| Net income growth, YoY | -74.4% | -34.1% | -8.0% | -40.5% | -6.5% | 24.0% | -20.4% | 101.8% | -37.5% | 5.7% |
| EPS growth, YoY | -73.5% | -33.6% | -8.1% | -37.3% | -2.2% | 32.9% | -13.9% | 102.4% | -36.6% | 11.1% |
| Gross margin | 78.3% | 81.1% | 80.8% | 80.6% | 81.6% | 81.6% | 82.3% | 83.1% | 82.9% | 82.1% |
| Operating margin | 4.0% | 7.8% | 10.1% | 10.8% | 14.3% | 15.6% | 13.8% | 15.8% | 12.7% | 13.8% |
| Net margin | 1.2% | 4.9% | 6.9% | 6.9% | 9.8% | 11.0% | 9.5% | 10.6% | 6.0% | 9.9% |
| Free cash flow margin | 0.9% | 6.0% | 6.1% | 9.4% | 9.1% | 12.8% | 10.4% | 11.8% | 10.6% | 10.4% |
| Return on equity | 2.0% | 7.9% | 12.8% | 16.0% | 29.5% | 28.2% | 28.6% | 32.3% | 17.2% | 30.8% |
| Return on assets | 1.4% | 5.6% | 10.1% | 11.6% | 20.2% | 19.5% | 19.4% | 22.8% | 12.0% | 21.3% |
| Current ratio | 2.24 | 2.00 | 3.52 | 2.67 | 2.27 | 2.53 | 2.42 | 2.64 | 2.41 | 2.01 |
| Line item | Jul 4, 2026 | Apr 4, 2026 | Jan 3, 2026 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 28, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 30, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $223.27M | $250.22M | $226.20M | $213.67M | $235.85M | $249.54M | $213.61M | $200.22M | $212.87M | $227.80M | $221.08M | $213.37M |
| Cost of revenue | $48.34M | $59.44M | $49.41M | $48.81M | $50.18M | $52.45M | $38.55M | $39.26M | $40.33M | $43.07M | $42.32M | $42.53M |
| Gross profit | $174.93M | $190.78M | $176.79M | $164.85M | $185.66M | $197.09M | $175.06M | $160.96M | $172.54M | $184.73M | $178.76M | $170.84M |
| Selling, general and admin | $82.32M | $88.25M | $78.08M | $85.95M | $81.91M | $91.44M | $73.35M | $61.30M | $64.33M | $64.30M | $58.66M | $63.30M |
| Operating income | -$20.00M | $13.87M | $3.82M | $1.22M | $16.72M | $15.67M | $8.21M | $15.60M | $17.84M | $24.67M | $24.22M | $17.61M |
| Interest expense | $0 | $240.0K | $123.0K | $49.0K | $259.0K | $411.0K | $129.0K | $49.0K | $51.0K | $52.0K | $145.0K | $43.0K |
| Pre-tax income | -$18.90M | $15.46M | $4.18M | $1.79M | $18.82M | $16.74M | $10.43M | $18.61M | $20.20M | $27.11M | $26.61M | $20.53M |
| Income tax | $9.05M | $8.51M | $5.77M | $8.46M | $8.37M | $7.45M | $5.95M | $8.00M | $9.77M | $10.57M | $9.85M | $9.18M |
| Net income | -$21.38M | $7.51M | -$1.77M | -$6.52M | $9.65M | $9.40M | $4.45M | $10.61M | $10.43M | $16.54M | $16.77M | $11.35M |
| EPS, basic | -$1.16 | $0.41 | -$0.07 | -$0.36 | $0.52 | $0.49 | $0.23 | $0.56 | $0.55 | $0.86 | $0.88 | $0.59 |
| EPS, diluted | -$1.16 | $0.41 | -$0.07 | -$0.36 | $0.52 | $0.49 | $0.23 | $0.56 | $0.54 | $0.86 | $0.87 | $0.59 |
| Diluted shares | 18.5M | 18.4M | - | 18.3M | 18.5M | 19.1M | - | 19.1M | 19.2M | 19.3M | - | 19.4M |
| Line item | Jul 4, 2026 | Apr 4, 2026 | Jan 3, 2026 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 28, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 30, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash and equivalents | $168.56M | $162.75M | $158.38M | $145.35M | $151.34M | $179.61M | $181.77M | $364.89M | $332.42M | $328.34M | $330.42M | $307.08M |
| Receivables | $3.34M | $9.66M | $4.29M | - | - | - | - | - | - | - | - | - |
| Inventory | $86.34M | $96.36M | $102.61M | $90.78M | $83.27M | $73.56M | $69.73M | $63.98M | $61.83M | $60.87M | $61.45M | $60.08M |
| Current assets | $281.07M | $294.23M | $288.40M | $264.06M | $261.87M | $281.39M | $279.19M | $451.19M | $419.08M | $421.07M | $417.75M | $390.46M |
| Goodwill | $109.14M | $138.13M | $137.96M | $144.29M | $144.23M | $144.22M | $144.17M | $17.20M | $16.84M | $16.90M | $17.10M | $16.80M |
| Total assets | $703.21M | $738.97M | $742.91M | $726.59M | $734.53M | $746.60M | $748.19M | $671.31M | $631.42M | $629.27M | $632.76M | $601.15M |
| Current liabilities | $105.67M | $117.24M | $128.56M | $118.66M | $121.63M | $137.38M | $139.63M | $114.78M | $103.90M | $112.63M | $118.84M | $112.56M |
| Total liabilities | $132.24M | $144.18M | $156.64M | $145.04M | $148.97M | $162.72M | $161.86M | - | - | - | $135.56M | - |
| Shareholders' equity | $526.31M | $543.55M | $533.10M | $528.07M | $531.06M | $529.76M | $532.11M | $533.09M | $512.21M | $499.99M | $497.20M | $470.39M |
| Line item | Jul 4, 2026 | Apr 4, 2026 | Jan 3, 2026 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 28, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 30, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Operating cash flow | $23.32M | $9.76M | -$3.39M | -$1.96M | $12.22M | $15.48M | $5.79M | $29.53M | $7.99M | $17.68M | $26.02M | $22.23M |
| Capital expenditures | $3.15M | $2.65M | $2.79M | $3.20M | $5.03M | $2.80M | $1.80M | $2.40M | $2.67M | $3.20M | $7.32M | $1.45M |
| Free cash flow | $20.16M | $7.11M | -$6.18M | -$5.16M | $7.19M | $12.68M | $3.98M | $27.14M | $5.32M | $14.48M | $18.70M | $20.78M |
| Investing cash flow | -$4.06M | -$2.60M | $1.11M | -$3.20M | -$4.16M | -$3.88M | -$205.14M | -$2.34M | -$1.55M | -$4.07M | -$7.32M | -$1.45M |
| Financing cash flow | -$14.03M | -$3.64M | $13.45M | -$979.0K | -$38.61M | -$14.47M | $22.93M | -$78.0K | -$1.35M | -$11.95M | $658.0K | -$11.64M |
| Share repurchases | $0 | $0 | $0 | $0 | $15.21M | $12.30M | $0 | $0 | $0 | $9.44M | $0 | $11.60M |
| Stock-based compensation | $3.40M | $3.45M | $3.75M | $3.58M | $3.62M | $2.88M | $3.61M | $3.54M | $3.73M | $3.67M | $3.64M | $3.67M |
| Depreciation and amortization | $7.67M | $8.28M | $8.56M | $7.92M | $7.74M | $8.34M | $4.00M | $3.57M | $3.81M | $3.16M | $2.91M | $3.27M |
| Line item | Jul 4, 2026 | Apr 4, 2026 | Jan 3, 2026 | Sep 27, 2025 | Jun 28, 2025 | Mar 29, 2025 | Dec 28, 2024 | Sep 28, 2024 | Jun 29, 2024 | Mar 30, 2024 | Dec 30, 2023 | Sep 30, 2023 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue growth, YoY | -5.3% | 0.3% | 5.9% | 6.7% | 10.8% | 9.5% | -3.4% | -6.2% | -10.6% | -8.3% | -3.0% | -8.5% |
| Net income growth, YoY | - | -20.1% | - | - | -7.4% | -43.1% | -73.4% | -6.5% | -39.7% | -10.0% | 31.0% | -24.0% |
| EPS growth, YoY | - | -16.3% | - | - | -3.7% | -43.0% | -73.6% | -5.1% | -39.3% | -9.5% | 31.8% | -24.4% |
| Gross margin | 78.3% | 76.2% | 78.2% | 77.2% | 78.7% | 79.0% | 82.0% | 80.4% | 81.1% | 81.1% | 80.9% | 80.1% |
| Operating margin | -9.0% | 5.5% | 1.7% | 0.6% | 7.1% | 6.3% | 3.8% | 7.8% | 8.4% | 10.8% | 11.0% | 8.3% |
| Net margin | -9.6% | 3.0% | -0.8% | -3.1% | 4.1% | 3.8% | 2.1% | 5.3% | 4.9% | 7.3% | 7.6% | 5.3% |
| Free cash flow margin | 9.0% | 2.8% | -2.7% | -2.4% | 3.0% | 5.1% | 1.9% | 13.6% | 2.5% | 6.4% | 8.5% | 9.7% |
| Current ratio | 2.66 | 2.51 | 2.24 | 2.23 | 2.15 | 2.05 | 2.00 | 3.93 | 4.03 | 3.74 | 3.52 | 3.47 |
Source: XBRL data USANA Health Sciences Inc. files with the SEC, latest filing dated Aug 13, 2026 (see filings on SEC EDGAR). Provided for information only, not investment advice. Check the filing before relying on a number.
* Worked out from the filings rather than stated in them: Q4 is the full year less the first nine months.
Per-share figures and share counts are restated for stock splits the filings show: 2-for-1, first reported Mar 1, 2017.
EPS growth is left out where the share count moved enough to suggest a split the filings do not show. Growth rates need a positive starting figure. CAGR is compound annual growth between fiscal years. The CSV holds every period on file, in full figures, from the same SEC filings.
| Company | Revenue | Growth | Net income | Net margin | Market cap |
|---|---|---|---|---|---|
| USNA | $913.36M | +1.6% | -$22.16M | -2.4% | $255.9M |
| PM | $43.14B | +7.9% | $10.71B | 24.8% | $301.01B |
| BTI | £25.61B | -1.0% | £7.76B | 30.3% | $129.81B |
| MO | $23.52B | +0.5% | $8.12B | 34.5% | $126.11B |
| DFTX | - | - | -$337.48M | - | $4.76B |
| RGC | - | - | -$11.70M | - | $2.79B |
| TRLV | $1.08B | -9.1% | -$445.60M | -41.2% | $2.12B |
| RLX | CN¥3.96B | +44.0% | CN¥921.87M | 23.3% | $1.94B |
| CRON | $271.85M | +54.3% | $63.36M | 23.3% | $1.30B |